Skip to content

Vera Therapeutics VERA Book value per share

Book value per share at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$75.54+18.8%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$1.07+189%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$4.12+68.6%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$23.29+2,285%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$7.43-22.1%
Immunome logo
ImmunomeIMNM
$5.20+34.5%

Other financials

Income statement

See full
Operating income-$125.1M-119%
Net income-$121.0M-134%
EPS (diluted)-$1.69-109%

Balance sheet

See full
Cash & equivalents$114.4M+108%
Total debt$75.0M+37.8%
Total equity$499.7M-6.6%
Total assets$621.7M+1.9%

Cash flow

See full
Operating cash flow-$106.5M-95.8%
CapEx$23.0K-87.7%
Free cash flow-$106.5M-95.1%

Valuation

See full
Market cap$2.74B+87.5%
Enterprise value$2.7B+85.0%

Returns & leverage

See full
Return on equity-71.3%+296pp
Debt / equity0.2×0.0×
Current ratio13.6×-14.0×

Where this comes from

Calculated from Vera Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vera Therapeutics's book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vera Therapeutics's book value per share?
Vera Therapeutics (VERA) reported book value per share of $6.99 in Q1 2026.
How has Vera Therapeutics's book value per share changed year-over-year?
Vera Therapeutics's book value per share decreased by 16.8% year-over-year, from $8.40 to $6.99.
What is the long-term trend for Vera Therapeutics's book value per share?
Over 5 years (2020 to 2025), Vera Therapeutics's book value per share has grown at a -49.2% compound annual growth rate (CAGR), from -$279.24 to $9.41.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.